<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41839">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01875224</url>
  </required_header>
  <id_info>
    <org_study_id>IM103-303</org_study_id>
    <nct_id>NCT01875224</nct_id>
  </id_info>
  <brief_title>Comparison of NODAT in Kidney Transplant Patients Receiving Belatacept Versus Standard Immunosuppression</brief_title>
  <official_title>Open-Label, Randomized Comparison of NODAT in Renal Transplant Patients Receiving a Nulojix (Belatacept) Regimen Versus Standard Therapy Immunosuppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to determine if belatacept is an appropriate alternative
      immunosuppressive medication (reducing the immune system's effect) when a kidney transplant
      patient develops new onset diabetes after transplant (NODAT).  Patients who are diagnosed
      with NODAT will be approached with the opportunity to participate in this study.  If they
      agree to participate, they will be randomized one-to-one (like a coin flip) to the study arm
      (belatacept) or the control arm (their current medication regimen).  If a patient is
      randomized to the study arm, they will be tapered off of their current regimen when they
      have started receiving their monthly belatacept infusions.  The control arm will mean the
      patient will continue their current, standard of care medications, but following the
      tacrolimus trough levels indicated within the study protocol.  Different laboratory tests
      (i.e. fasting blood glucose) will be measured during the study to monitor the progression of
      NODAT in all patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Increased insulin sensitivity</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Increase in insulin sensitivity (HOMA-S) as calculated below:
FIRI = fasting plasma insulin level
FPG = fasting plasma glucose level
HOMA-S (insulin sensitivity) is calculated as 22.5 / (FIRI * FPG)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Decreased insulin resistance</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Decreased insulin resistance (HOMA-IR) as measured below:
FIRI = fasting plasma insulin level
FPG = fasting plasma glucose level
HOMA IR (insulin resistance) is calculated as (FIRI * FPG) / 22.5</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>New Onset Diabetes After Transplant</condition>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Belatacept and CellCept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Belatacept administered based on patient's weight once a month after initial period, Cellcept taken twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tacrolimus and CellCept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tacrolimus and CellCept taken twice daily based on patient response.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belatacept</intervention_name>
    <arm_group_label>Belatacept and CellCept</arm_group_label>
    <other_name>Nulojix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Standard administration of tacrolimus</description>
    <arm_group_label>Tacrolimus and CellCept</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent must be given by patient.

          -  Adult patients between age 18 and 65

          -  Thymoglobulin induction at the time of transplant

          -  Patient must be Epstein-Barr Virus seropositive

        Exclusion Criteria:

          -  Patient who received an blood type incompatible transplant, or with T-cell or B-cell
             positive crossmatch

          -  Patients with Hepatitis B, Hepatitis C, HIV or a clinically significant systemic
             infection within 30 days prior to transplant

          -  History of stroke, severe cardiac disease or cardiac failure
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Kaplan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruce Kaplan, MD</last_name>
    <phone>520-626-6371</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rochelle Byrne, RN</last_name>
    <phone>520-626-9603</phone>
    <email>rbyrne@deptofmed.arizona.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rochelle Byrne, RN</last_name>
      <phone>520-626-9603</phone>
      <email>rbyrne@deptofmed.arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Bruce Kaplan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 7, 2013</lastchanged_date>
  <firstreceived_date>May 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Arizona</investigator_affiliation>
    <investigator_full_name>Bruce Kaplan</investigator_full_name>
    <investigator_title>Chief of Abdominal Transplantation</investigator_title>
  </responsible_party>
  <keyword>kidney transplant</keyword>
  <keyword>diabetes after transplant</keyword>
  <keyword>belatacept</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
